Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Targeting chemo-resistant leukemia by chemotherapy-DNT combination therapy
FY 2015-16
Summary
Acute myeloid leukemia (AML) is the most common form of acute blood cancer in adults and is associated with a very low rate of long term survival. Although many patients reach remission after conventional chemotherapy, leukemia relapse occurs in most patients within 2 years due to persisting chemotherapy-resistant leukemic stem cells. A primary focus of our lab is to develop a novel adoptive T cell therapy for AML by targeting chemotherapy-resistant leukemic cells in order to improve outcomes in AML patients. We have demonstrated that a unique type of immune cell called double negative T cells (DNTs) can specifically target and kill AML cells while leaving normal bone marrow and blood cells unharmed. My project will study the effectiveness of combining chemotherapy and DNT therapy to eliminate chemotherapy-resistant AML and identify underlying mechanisms by which the two therapies work together to target AML cells. Specifically, I will examine in depth the mechanisms by which chemotherapy sensitizes leukemic cells to killing by DNTs. Furthermore, I will determine how well the combination therapy targets leukemic stem cells in an animal model. These studies will not only validate the capability of chemotherapy-DNT dual therapy against leukemic stem cells, but also further our knowledge on the interactions between conventional chemotherapy and novel cellular therapies. Ultimately, this will contribute to the optimization of cellular therapies that may provide more effective treatments to increase the rate of disease-free survival in AML patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349922
Name
Chen Branson
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting chemo-resistant leukemia by chemotherapy-DNT combination therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aml; Chemotherapy; Immunology; Immunotherapy; Leukemia; Stem Cell
Abstract
Acute myeloid leukemia (AML) is the most common form of acute blood cancer in adults and is associated with a very low rate of long term survival. Although many patients reach remission after conventional chemotherapy, leukemia relapse occurs in most patients within 2 years due to persisting chemotherapy-resistant leukemic stem cells. A primary focus of our lab is to develop a novel adoptive T cell therapy for AML by targeting chemotherapy-resistant leukemic cells in order to improve outcomes in AML patients. We have demonstrated that a unique type of immune cell called double negative T cells (DNTs) can specifically target and kill AML cells while leaving normal bone marrow and blood cells unharmed. My project will study the effectiveness of combining chemotherapy and DNT therapy to eliminate chemotherapy-resistant AML and identify underlying mechanisms by which the two therapies work together to target AML cells. Specifically, I will examine in depth the mechanisms by which chemotherapy sensitizes leukemic cells to killing by DNTs. Furthermore, I will determine how well the combination therapy targets leukemic stem cells in an animal model. These studies will not only validate the capability of chemotherapy-DNT dual therapy against leukemic stem cells, but also further our knowledge on the interactions between conventional chemotherapy and novel cellular therapies. Ultimately, this will contribute to the optimization of cellular therapies that may provide more effective treatments to increase the rate of disease-free survival in AML patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen, Branson
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~